8-K: PROCEPT BioRobotics Reports Strong Q1 2024 Results, Raises Full-Year Revenue Guidance

PROCEPT BioRobotics announced a significant 83% increase in first-quarter revenue and raised its full-year revenue guidance to $213.5 million.

Summary

• PROCEPT BioRobotics reported a total revenue of $44.5 million for the first quarter of 2024, which is an 83% increase compared to the same period in 2023.
• U.S. revenue reached $40.2 million, showing an 85% growth year-over-year, driven by system sales and increased handpiece revenue.
• U.S. handpiece and consumable revenue was $23.6 million, a 101% increase compared to the prior year.
• The company sold 38 robotic systems in the U.S. during the first quarter.
• U.S. system and rental revenue was $14.2 million, a 62% increase year-over-year.
• International revenue grew by 65% to $4.3 million.
• The gross margin improved to 56% in Q1 2024, up from 51% in the same period last year.
• Operating expenses increased to $52.7 million, up from $40.9 million in the prior year, due to sales and marketing expansion and increased R&D.
• The net loss for the quarter was $26.0 million, an improvement from a $28.5 million loss in the prior year.
• Adjusted EBITDA loss was $20.4 million, compared to a loss of $23.9 million in the prior year.
• The company increased its full-year 2024 revenue guidance to $213.5 million, representing a 57% growth over the prior year.
• Full-year 2024 gross margin is projected to be approximately 58% to 59%.
• The company projects a full-year 2024 Adjusted EBITDA loss of $70.0 million.

Sentiment

Score: 8

Explanation: The document conveys a very positive sentiment due to strong revenue growth, improved gross margins, and increased full-year guidance. While the company is still operating at a loss, the improvements and positive outlook suggest a strong trajectory.

Positives

• The company experienced significant revenue growth across all segments, particularly in the U.S. market.
• The gross margin improved due to strong operational execution and improved overhead absorption.
• The company has increased its full-year revenue guidance, indicating confidence in future performance.
• The net loss and adjusted EBITDA loss improved compared to the prior year period.
• The company has a strong cash position with $225.6 million in cash and short-term investments.

Negatives

• Operating expenses increased significantly due to sales and marketing expansion and increased R&D.
• The company continues to operate at a net loss and an adjusted EBITDA loss.
• The company has long-term borrowings of $52.0 million.

Risks

• The company's future performance is subject to risks and uncertainties, as detailed in their SEC filings.
• The company's forward-looking statements are based on current expectations and are not guarantees of future performance.
• Increased operating expenses could impact future profitability if not managed effectively.
• The company's success depends on the continued adoption of Aquablation therapy.

Future Outlook

The company has increased its full-year 2024 revenue guidance to $213.5 million and projects a gross margin of approximately 58% to 59%. They also anticipate an adjusted EBITDA loss of $70.0 million for the full year.

Management Comments

• Reza Zadno, Chief Executive Officer, stated that the company started 2024 with strong revenue growth exceeding 80% and demonstrated disciplined management of operating expenses.
• Reza Zadno also mentioned that the company is in a great position to continue leveraging overhead expenses to improve gross margins throughout the year.
• Management is confident in hitting their long-term growth targets due to an expanded commercial team and growing demand for Aquablation therapy.

Industry Context

This announcement highlights the growing adoption of robotic surgery in urology, particularly for treating BPH. PROCEPT BioRobotics is positioned to capitalize on this trend with its Aquablation therapy, which is gaining traction in the market.

Comparison to Industry Standards

• Intuitive Surgical, a leader in robotic surgery, reported a 12% increase in system placements in their most recent quarter, while PROCEPT BioRobotics sold 38 systems in the US alone, indicating a strong growth trajectory.
• Globally, the surgical robotics market is experiencing rapid growth, with companies like Stryker and Medtronic also investing heavily in this space. PROCEPT's 83% revenue growth significantly outpaces the average market growth rate.
• Compared to other medical device companies, PROCEPT's gross margin of 56% is competitive, and the projected full-year gross margin of 58-59% indicates further improvement.
• While many medical device companies are focused on a broader range of surgical applications, PROCEPT's focus on urology and BPH allows them to specialize and potentially gain a larger market share in this specific area.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and increased guidance.
• Employees may benefit from the company's growth and expansion.
• Customers (hospitals and surgeons) will have access to an increasingly adopted and effective treatment option.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company's improved financial performance favorably.

Next Steps

• The company will host a conference call to discuss the first quarter 2024 financial results on May 1, 2024.
• The company will continue to focus on expanding its commercial organization and driving adoption of Aquablation therapy.
• The company will continue to leverage overhead expenses to improve gross margins throughout the year.

Key Dates

Keywords

surgical robotics, urology, Aquablation therapy, robotic systems, revenue growth, gross margin, financial results, PROCEPT BioRobotics, BPH, medical devices